Nitrosigine®,
does it really help with Improved exercise pump, blood flow, endurance, and recovery?
research showsHuman studies using 1,500 mg/day report increased plasma arginine and selected vigor or creatine-kinase signals. The pivotal exercise study, however, was a four-day manufacturer-linked crossover trial in 16 men, and between-group differences in femoral blood flow and leg circumference were not significant. Independent replication for repetitions, power, or endurance is absent, yielding C with 40 points.
ads claimMarketing converts increases in plasma arginine or nitric-oxide-related measures into established stronger pumps, greater blood flow, endurance, and faster recovery. The data center on concentrations, salivary nitrite, circumference, creatine kinase, and mood scales.
Useful facts when choosing a product
- The core research dose is 1,500 mg/day of Nitrosigine.
- Korean consumers may encounter single-ingredient or preworkout blends through cross-border purchasing and online sellers; actual content, formal import status, and labeling require product-specific checks.
- Effects of blends containing caffeine, citrulline, beta-alanine, or creatine cannot be attributed to Nitrosigine alone.
- No adverse events occurred in a 14-day study of 10 men, but long-term, pregnancy, lactation, and antihypertensive or vasodilator co-use data are insufficient.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.inositol-stabilized-arginine-silicate.UNK.exercise-pump-blood-flow-endurance-and-recovery.improve.placeboUnknown > Inositol-stabilized arginine silicate > Unknown > exercise pump, blood flow, endurance, and recovery > Improvement claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
The 2015 Kalman study was a 14-day open-label single-arm study in 10 healthy men; it found higher plasma arginine and limited salivary-nitrite changes but did not measure exercise performance. The 2015 Rood-Ojalvo study was a double-blind placebo-controlled crossover trial in 16 men. Vigor and selected creatine-kinase results were positive, but blood-flow and circumference comparisons were non-significant and it was not a direct endurance or power trial. Both studies were small and closely linked to the trademark developer.
Why this is classified as C (40)
As with arginine (039) and citrulline (078), nitric-oxide and blood-flow surrogates were separated from actual performance. Small manufacturer-linked signals, non-significant key comparisons, and absent direct replication place the verdict at the bottom of C with 40 points.
Counterpoint. Small physiological changes could matter to some users seeking a pump, but the evidence cannot be generalized to endurance, power, or recovery.
Rejudgment record. New verdict — Positive arginine and nitric-oxide surrogate signals for a proprietary ingredient, but non-significant key blood-flow and pump comparisons and no independent replication of performance, endurance, or recovery
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Exercise pump, blood flow, and nitric-oxide-related surrogate markers | C | Plasma arginine increased, but between-group comparisons for femoral blood flow and leg circumference were non-significant at p=0.20 and p=0.070. |
| Improved actual exercise performance, endurance, and recovery | ? | In an n=16 trial femoral blood flow, leg circumference and fatigue comparisons were null, but the sample was small; no human trial has adequately tested actual reps, power, endurance or recovery. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Rood-Ojalvo S et al. 2015 | Double-blind placebo-controlled crossover trial; conference abstract | 16 | Two authors affiliated with Nutrition 21; trademark-ingredient study | POMS, femoral blood flow, leg circumference, creatine kinase, and lactate dehydrogenase | Vigor and selected creatine-kinase results were positive, but key blood-flow, pump, and fatigue comparisons were non-significant. | Key |
| Kalman DS et al. 2015 | Open-label single-arm pharmacokinetic and safety study | 14 | Nutrition 21 product; the paper reported no conflicts | Arginine, silicon, salivary nitrite, and adverse events | Arginine increased, but exercise performance was not measured. | Surrogate |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-18).
Final verification and publication gate: Codex · Evidence date: 2026-07-18 · Corrections: none
Cite this verdict
[Chamgap] Nitrosigine® x exercise pump, blood flow, endurance, and recovery — Evidence Grade C·40. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/sports/nitrosigine-exercise-pump-performance-recovery/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.